
GenVec, Inc. (Nasdaq:GNVC) announced that it has received an Advanced Technology Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases, of the National Institutes of Health, to support the Company's efforts to develop vaccines for the prevention of respiratory syncytial virus (RSV).
Click here for full Story http://www.medicalnewstoday.com/articles/106915.php |